Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
7,819,192
-
Total 13F shares
-
1,088,077
-
Share change
-
+37,485
-
Total reported value
-
$2,346,525
-
Put/Call ratio
-
68%
-
Price per share
-
$2.16
-
Number of holders
-
30
-
Value change
-
+$81,424
-
Number of buys
-
11
-
Number of sells
-
11
Institutional Holders of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) as of Q4 2023
As of 31 Dec 2023,
PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,088,077 shares.
The largest 10 holders included
K2 PRINCIPAL FUND, L.P., GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, EQUITEC PROPRIETARY MARKETS, LLC, SABBY MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, DIMENSIONAL FUND ADVISORS LP, BlackRock Inc., CITADEL ADVISORS LLC, and Schonfeld Strategic Advisors LLC.
This page lists
30
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.